In this study, we demonstrated that LukS-PV targeting C5aR1 inhibits HCC cell proliferation by the HDAC7-Wnt/β-catenin axis, suggesting the strong potential of LukS-PV as a therapeutic cancer drug for HCC treatment. The gene discussed is C5AR1; the disease is cancer.